Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability

Highlights of the Interim Results as of June 30, 2023: Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% Adjusted Non-IFRS net profit…